Bangladesh approves Janssen vaccine

Staff Correspondent

16 June, 2021 12:00 AM printer

The Directorate General of Drug Administration (DGDA) has given emergency use authorisation to Janssen Covid-19 vaccine developed by a Belgian drug manufacturer.

The DGDA gave the approval on June 15, after its local agent Line Director (MNC & AH) of Directorate General of Health Services (DGHS) applied for its approval for emergency use in Bangladesh, said the DGDA.

The DGHS has been listed as the first distributor of a Covid-19 vaccine as a government agency.

The Janssen is the sixth vaccine which has been given the emergency use authorization.

Janssen COVID-19 vaccine is manufactured by Janssen-Cilag International NV, Belgium, the DGDA said.

On March 12 this year, the World Health Organisation (WHO) listed the COVID-19 vaccine Ad26.COV2.S, developed by Janssen (Johnson & Johnson), for emergency use in all countries and for COVAX roll-out.

The Janssen vaccine can be kept for three months at 2-8°C and it has a long shelf life of two years.

It is the first single-dose Covid-19 vaccine approved for emergency use in the country. Earlier, the DGDA approved five double-dose Covid-19 vaccines for emergency use in Bangladesh.

The Janssen vaccine is indicated for active immunization to prevent Covid-19 caused by SARS-CoV-2, in individuals 18 years of age and older.

Bangladesh also approved Oxford-AstraZeneca (Covishield) vaccine manufactured by Serum Institute of India, Sputnik V produced by Generium Joint Stock Company of Russia, ‘CoronaVac’, manufactured by Sinovac Life Science Co Ltd and Sinopharm produced by Beijing Institute of Biological Products Co. Ltd of China and Pfizer-BioNTech vaccine.